Intellect Neurosciences Inc. (fka ILNS)

[buckiii2]

Presented by the New York Academy of Sciences and the Global CEO Initiative on Alzheimer's Disease
Reported by Hannah Rice | Posted March 3, 2015
Overview
Alzheimer's disease (AD) research is greatly underfunded compared to other major diseases. But the socioeconomic costs of AD are huge and growing as the population ages. Because existing drugs only ameliorate symptoms and do not attack the underlying biology, without a treatment breakthrough the cost of AD care is set to skyrocket. The U.S. alone will spend an estimated $20 trillion on dementia care over the next 40 years, with costs exceeding $1 trillion annually by 2050—which is greater than the 2014 budget for Medicare and Medicaid combined. In December 2013 the Group of Eight (G8) nations took on the global dementia challenge, committing to "collectively and significantly" increase financial resources for Alzheimer's research.

A major, and ambitious, goal is to develop a disease-modifying drug for AD by 2025. Much of the effort to establish new financing focuses on underfunded stages of research. But funds are also needed in other areas of disease management to incentivize drug development, find new biomarkers and targets, improve infrastructure, and pay for care delivery.

On December 11, 2014, the Innovative Models of Funding for Alzheimer's Disease and Dementia: Ideas and Implementation Workshop convened by the Academy and CEOi explored new public and private funding mechanisms for AD. Speakers presented ideas such as crowd equity, social impact investing, hybrid philanthropy/venture capital models, accelerators, and megafunds that could be applied to different stages of research and care. The workshop also considered how policy changes could spur research, as well as how best to apply government funds.

Use the tabs above to find a meeting report and multimedia from this event.

Presentations available from:
Dennis Gillings, CBE, PhD (World Dementia Council)
Adam D. Grossman, JD, MBA (Give to Cure)
Andrew W. Lo, PhD (Massachusetts Institute of Technology)
Maike Stenull, MBA (Johnson & Johnson)
Clare Stroud, PhD (Institute of Medicine)

http://www.nyas.org/Publications/EBriefings/Detail.aspx?cid=03a2c5bd-aa4b-448b-9ea2-20c1ec9ccf50